Century Therapeutics, Inc. (IPSC): Price and Financial Metrics
GET POWR RATINGS... FREE!
IPSC Stock Price Chart Interactive Chart >
IPSC Price/Volume Stats
| Current price | $8.85 | 52-week high | $32.90 |
| Prev. close | $8.39 | 52-week low | $7.32 |
| Day low | $8.08 | Volume | 46,700 |
| Day high | $8.89 | Avg. volume | 106,797 |
| 50-day MA | $10.91 | Dividend yield | N/A |
| 200-day MA | $16.59 | Market Cap | 520.82M |
Century Therapeutics, Inc. (IPSC) Company Bio
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT or CAR-iNK candidate targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia. The company was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.
Latest IPSC News From Around the Web
Below are the latest news stories about Century Therapeutics Inc that investors may wish to consider to help them evaluate IPSC as an investment opportunity.
Century Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare ConferencePHILADELPHIA, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that members of the senior management team will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 16, 2022, at 1:40 PM ET. A live webcast of the event will be available on the Events & Presentations page of Century’s we |
2 Natural-Killer Cell Therapy Oncology Companies Investors Should WatchNatural-killer cell therapy is one of the most recent paradigms in cancer treatment, and two prominent companies working on this new technology are Fate Therapeutics Inc (NASDAQ: FATE ) and Century Therapeutics Inc (NASDAQ: IPSC ), an analyst at BofA Securities said in a note on Tuesday. The Biopharma Analyst: Tazeen Ahmad has a Buy rating and $112 price target on Fate shares. The analyst rates Century a Buy with a $34 price target. The Biopharma Thesis: Fate''s To-Date Progress Is Encouraging: Fate''s pipeline of NK assets are currently in the clinic for liquid tumors, Ahmad said in a note. These assets have shown robust response rates and a manageable safety profile, he added. A recent clinical update from the 2021 ASH conference vouches for the redosing potential of NK cells, the ana... |
What''s Behind Bristol Myers Squibb''s Latest Partnership?The big drugmaker is gaining access to Century Therapeutics'' off-the-shelf CAR-T programs. |
What's Behind Bristol Myers Squibb's Latest Partnership?Bristol Myers Squibb (NYSE: BMY) has made some big acquisitions in the past, and it's now hinting that more deals could be on the way. The pharmaceutical giant recently announced a smaller licensing agreement with Century Therapeutics (NASDAQ: IPSC) instead of a big acquisition. In this Motley Fool Live video, recorded on Jan. 12, Fool contributors Keith Speights and Brian Orelli discuss what's behind Bristol Myers Squibb's latest partnership. |
Inside the deal: Why Century Therapeutics picked Bristol Myers Squibb for its first Big Pharma mega-dealThe partnership could result in a multibillion-dollar payday for the Philadelphia cell therapy company. |
IPSC Price Returns
| 1-mo | -26.43% |
| 3-mo | -33.01% |
| 6-mo | -48.06% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -44.20% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...